Directing alternative splicing to conquer disease
In Memory of Our Co-Founder Dr. Melanie Tallent
NIH Grant Awarded ($670 K) to further Development of Drug to Treat Dravet Syndrome
NIH Grant Awarded ($340K) for Initial Drug Development of a Novel Alzheimer’s Disease Treatment.
AMPA GluA1-flip targeted oligonucleotide therapy paper published in PLOS One Journal
Investors & Partners
Dr. McArdle New CMC
Dr. James McArdle joins LifeSplice as Chemistry, Manufacturing, and Control Consultant